Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / series-b-preferred-consent.docx
series-b-preferred-consent.docx
Parties
Genome Dx Therapeutics Inc
Delaware General Corp
Stonebridge Capital Management III LLC
Dates
September 10, 2025
August 15, 2023
March 12, 2027
Amounts
$0.0001
$2,000,000
$8,000,000
$120,000,000
$3,000,000
Obligations
This Written Consent shall be effective as of September 10, 2025
Prompt notice of the taking of the action set forth herein shall be given to all holders of Series B Preferred Stock who have not consented hereto, to the extent required by Section 228(e) of the DGCL
pdf) transmission, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument
pdf) shall be effective as delivery of an original executed counterpart
All such agreements, instruments, and documents shall remain in full force and effect in accordance with their respective terms, and the undersigned expressly reserves all of its rights and remedies thereunder